Pharmaceuticals
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery
SINGAPORE, April 14, 2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based inSingapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for MLC1501 in traumatic brain injury (TBI). Moleac is dedicated in finding, dev...
2021-04-14 19:15
2012
Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company, presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Rese...
2021-04-13 14:55
3609
Psychobiotic PS128 improves mood and sleep quality in its first clinical study on anxiety and stress
TAIPEI, April 13, 2021 /PRNewswire/ -- Bened Biomedical's psychobiotic PS128 significantly improved insomnia, stress, and anxiety during a recent clinical trial. Participants were IT professionals under high levels of work-life stress. Psychobiotics are probiotics that yield specific mental healt...
2021-04-13 10:00
2747
Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL
SHANGHAI, China and GAITHERSBURG, U.S., April 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in h...
2021-04-13 08:00
3270
PharmAbcine presents the non-clinical data of PMC-309 at AACR 2021
DAEJEON, South Korea, April 12, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company presented an e-poster featuring the non-clinical data of PMC-309 at American Associatio...
2021-04-12 20:00
1479
Yiling Pharmaceutical doubled its performance through innovation in 2020
SHIJIAZHUANG, China, April 12, 2021 /PRNewswire/ -- Yiling Pharmaceutical (002603.SZ) released its 2020 annual report on Thursday. It achieved an operating revenue ofRMB 8.782 billion in 2020, with a year-on-year growth of 50.76%; and net profit attributed to equity holders ofRMB 1.219 billion, w...
2021-04-12 17:07
4662
Ascletis Announced Four Clinical and Preclinical Study Abstracts of NASH and HBV Accepted as Poster Presentations by the International Liver Congress™ 2021
HANGZHOU, China and SHAOXING, China, April 12, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) announces today that four clinical and preclinical study abstracts of NASH and HBV have been accepted by the International Liver Congress™ 2021 as poster presentations. The summary of the four abs...
2021-04-12 08:30
3394
Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations
SHANGHAI and HONG KONG, April 12, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and onco...
2021-04-12 08:00
2808
Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting
SUZHOU and SHANGHAI, China, April 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today presented updated long...
2021-04-10 21:33
5661
RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue
Independent Data Safety Monitoring Board unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 pneumonia based on review of unblinded safety data from the first 255 treated patients The 464-patient global Phase 2/3 COVID-19 study is ...
2021-04-09 19:00
4873
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
SHANGHAI, April 9, 2021 /PRNewswire/ -- Everest Medicines
2021-04-09 08:30
5879
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Chile
* Marks vaccine's first approval in South America, following Mexico, Pakistan, China and Hungary * Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions * 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination TI...
2021-04-08 21:17
7223
ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting
SHENZHEN, China, April 8, 2021 /PRNewswire/ -- ImmVira today announces that the company will be presenting its first innovative product, MVR-T3011, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting onJune 4-8 2021. Results from the first Phase 1 study of MVR-T3011 as an intr...
2021-04-08 20:47
2424
EyeYon Medical Announces Innovative Medical Device Designation Granted For EndoArt® In China
TEL-AVIV, Israel, April 8, 2021 /PRNewswire/ -- EyeYon Medical, an Israeli start-up company developing a variety of ophthalmic products for vision-threatening conditions, announces today that EndoArt® was granted the Innovative Device Status byChina's Center for Medical Device Evaluation, the ar...
2021-04-08 08:00
2556
Inmagene R&D Team expands with two new senior members joining the Company
SAN DIEGO and SHANGHAI and HANGZHOU, China, April 7, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") today announced that Dr.Anbo Xiang and Dr.Qian Xu joined the company. As CMO (China) and Senior VP, Operations, Dr. Xiang will be responsible for clinical development, operations, an...
2021-04-07 09:00
17446
WuXi Biologics Successfully Completed Pre-License Inspection and Routine GMP Inspection by U.S. FDA
WUXI, China, April 7, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has successfully completed both a Pre-License Inspection (PLI) and a routine GMP inspection by the U.S. FDA (FDA). T...
2021-04-07 08:22
22543
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S
SEONGNAM, South Korea, April 6, 2021 /PRNewswire/ -- Bridge Biotherapeutics Inc.(288330 KQ), a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced that the company has initiated the Phase 1/2 clinical trial assessing safety, tolerability, and anti-tumor activity...
2021-04-07 06:00
5393
Shanghai Genechem Co., Ltd. (Genechem) Announces Global Collaboration on Bispecific Antibodies
SHANGHAI, April 6,, 2021 /PRNewswire/ -- Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel drug target discovery and development of novel therapeutics, today announced the execution of a global collaboration with I-Mab (Nasdaq: IMAB), a Nasdaq-listed global bioph...
2021-04-06 22:26
38490
Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of glioma
BEIJING, and BRIDGEWATER, N.J., April 6, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), a global biopharmaceutical company, today announced that the European Medicine Agency (EMA) Committee for Orphan Medicinal Products ...
2021-04-06 20:53
3889
Brattea, a Leading Renal Denervation Company in China, Completes over $US20 Million Series B+ Financing, led by Kuanping Capital
SHANGHAI, April 6, 2021 /PRNewswire/ -- Brattea, a leading renal denervation (RDN) medical technology company inChina, announced today its successful completion of over$US20 million Series B+ financing led by healthcare private equity fund Kuanping Capital. New investors include Hengxu Capital, P...
2021-04-06 20:00
41154
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8873
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7709